These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 27713145

  • 21. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E, Canessa PA, Ferro P, Franceschini MC, Fontana V, Dessanti P, Pinelli V, Morabito A, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [Abstract] [Full Text] [Related]

  • 23. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [Abstract] [Full Text] [Related]

  • 24. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
    Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, Goparaju CM, Prokrym K, Canino C, Pass HI, Carbone M, Yang H.
    Clin Cancer Res; 2016 Jun 15; 22(12):3087-96. PubMed ID: 26733616
    [Abstract] [Full Text] [Related]

  • 25. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S.
    Int J Oncol; 2019 Jun 15; 54(6):2139-2148. PubMed ID: 30942424
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.
    Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ.
    BMJ Open; 2014 Feb 24; 4(2):e004145. PubMed ID: 24566531
    [Abstract] [Full Text] [Related]

  • 30. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T, Kataoka Y, Ikegaki S, Saito E, Matsumoto H, Kaku S, Shimada M, Hirabayashi M.
    PLoS One; 2017 Feb 24; 12(10):e0185850. PubMed ID: 28968445
    [Abstract] [Full Text] [Related]

  • 31. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Fontana V, Pistillo MP, Vigani A, Canessa PA, Berisso G, Giannoni U, Ferro P, Franceschini MC, Carosio R, Tonarelli M, Rossi C, Dessanti P, Roncella S.
    Anticancer Res; 2019 Sep 24; 39(9):5219-5223. PubMed ID: 31519636
    [Abstract] [Full Text] [Related]

  • 32. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.
    Clin Chem Lab Med; 2011 Oct 24; 49(10):1721-6. PubMed ID: 21692685
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
    Filiberti R, Parodi S, Libener R, Ivaldi GP, Canessa PA, Ugolini D, Bobbio B, Marroni P.
    Med Oncol; 2013 Jun 24; 30(2):543. PubMed ID: 23532816
    [Abstract] [Full Text] [Related]

  • 35. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.
    Clin Cancer Res; 2007 May 15; 13(10):2928-35. PubMed ID: 17504993
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
    Gao R, Wang F, Wang Z, Wu Y, Xu L, Qin Y, Shi H, Tong Z.
    Medicine (Baltimore); 2019 Apr 15; 98(14):e14979. PubMed ID: 30946324
    [Abstract] [Full Text] [Related]

  • 38. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
    Tsim S, Kelly C, Alexander L, McCormick C, Thomson F, Woodward R, Foster JE, Stobo DB, Paul J, Maskell NA, Chalmers A, Blyth KG.
    BMJ Open; 2016 Nov 24; 6(11):e013324. PubMed ID: 27884852
    [Abstract] [Full Text] [Related]

  • 39. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
    Ren R, Yin P, Zhang Y, Zhou J, Zhou Y, Xu R, Lin H, Huang C.
    Oncotarget; 2016 Dec 20; 7(51):84851-84859. PubMed ID: 27769044
    [Abstract] [Full Text] [Related]

  • 40. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND.
    Lung; 2014 Feb 20; 192(1):197-203. PubMed ID: 24170217
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.